Other Events ·
Outlook Therapeutics reported preliminary cash and cash equivalents of approximately $11.2 million as of June 30, 2026
OTLKOutlook Therapeutics, Inc.
Outlook Therapeutics reported preliminary cash and cash equivalents of approximately $11.2 million as of June 30, 2026. The company announced that the FDA approved LYTENAVA (bevacizumab-vikg) for neovascular age-related macular degeneration on July 24, 2026, and filed amended risk factors reflecting this approval. Additionally, Outlook terminated its At The Market Offering Agreement with H.C. Wainwright & Co., effective August 10, 2026, though the underlying sales agreement remains in force. The company operates in the biopharmaceutical industry, developing and commercializing treatments for ophthalmic diseases.